A team of international researchers, including Case Western Reserve University School of Medicine, have discovered regions of the genome that affect the severity of the genetic disease cystic fibrosis (CF), the most common lethal genetic disease affecting children in North America. The findings provide insight into the causes of the wide variation in lung disease severity experienced by CF patients. It also points the way to new diagnostic markers and therapeutic approaches for this and more common lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).
“For the past 4 decades, the lives of CF patients have been extended tremendously, however they are still cut too short. This discovery of new gene variants provides new avenues to explore to extend their lives,” says Mitchell Drumm, PhD (pictured), professor of pediatrics and genetics and interim vice chair for research in the Department of Pediatrics at Case Western Reserve University School of Medicine and University Hospitals Rainbow Babies & Children’s Hospital.
This study is among the first reported genome-wide scans of a single gene disorder. It was the work of the North America CF Gene Modifier Consortium, which brought together dozens of investigators from the United States and Canada to identify which regions of the genome are associated with lung disease severity in almost 3,500 CF patients.
CF is a genetic disease affecting every organ system, causes the lungs to clog up with infection-prone, thick, sticky mucus. Though every CF patient carries the CF gene, known as the cystic fibrosis transmembrane conductance regulator or CFTR, symptoms can vary widely from patient to patient. For instance, some patients can have such severe lung disease that they are near death at the age of 10, whereas others can have nearly normal lung function at the age of 35.
For the last decade, Dr. Drumm and his colleagues have been searching for other genetic factors that modify the effects of the disease-causing mutations in the CFTR gene, either improving or exacerbating the disease as it unfolds.
Genome-wide association studies, or "GWAS," as they are called, allow simultaneous examination of hundreds of thousands of genetic variants. The Consortium analyzed 570,725 variants across the chromosomes of 3,467 CF patients and found that variants in a small region of chromosome 11 and another small region on chromosome 20 consistently associated with the severity of a patient's lung disease.
Members of the Consortium are now trying to understand how the variants in these regions affect the disease’s progression.
“We have whittled down our scope from 30,000 genes down to 4. For one of the genes we’ve identified, there are already medications on the market regulating it but for other conditions. We now have the opportunity to test existing drugs, ones that we never would have thought of but may in fact turn out to help CF patients.”
“This cystic fibrosis discovery showcases the valuable information that can be obtained when scientists work together on these genome wide association studies,” said Susan B. Shurin, M.D., acting director of the National Heart, Lung, and Blood Institute (NHLBI). “Now we are closer to understanding why patients with the exact same genetic mutation in the cystic fibrosis gene have such widely varying manifestations of lung disease, and closer to finding new therapies.”
Illustration: Case Western Reserve University.
Case Western Reserve University School of Medicine News Release (05/23/11)
Medical News Today (05/23/11)
Abstract (Nature Genetics; 43, 539-546 (05/21/11))